196 related articles for article (PubMed ID: 27624328)
1. Impact of bivalirudin on mortality and bleeding complications in acute coronary syndrome patients undergoing invasive revascularization : A real world experience.
Rohla M; Tentzeris I; Freynhofer MK; Farhan S; Jarai R; Egger F; Weiss TW; Wojta J; Geppert A; Kastrati A; Stone GW; Huber K
Wien Klin Wochenschr; 2016 Dec; 128(23-24):906-915. PubMed ID: 27624328
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes.
Feldman DN; Minutello RM; Bergman G; Moussa I; Wong SC
Catheter Cardiovasc Interv; 2010 Oct; 76(4):513-24. PubMed ID: 20882655
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Safety and Efficacy of Unfractionated Heparin Versus Bivalirudin in Patients Undergoing Percutaneous Coronary Intervention.
Rehmani A; Judkins C; Whelan A; Nguyen M; Schultz C
Heart Lung Circ; 2017 Dec; 26(12):1277-1281. PubMed ID: 28377232
[TBL] [Abstract][Full Text] [Related]
4. Comparison of bivalirudin with heparin versus abciximab with heparin for primary percutaneous coronary intervention in "Real World" practice.
Showkathali R; Davies JR; Parker M; Taggu W; Tang KH; Clesham GJ; Gamma RA; Sayer JW; Aggarwal RK; Kelly PA
Cardiovasc Revasc Med; 2013; 14(5):289-93. PubMed ID: 23972537
[TBL] [Abstract][Full Text] [Related]
5. Bleeding risk comparing targeted low-dose heparin with bivalirudin in patients undergoing percutaneous coronary intervention: results from a propensity score-matched analysis of the Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) registry.
Bangalore S; Cohen DJ; Kleiman NS; Regev-Beinart T; Rao SV; Pencina MJ; Mauri L;
Circ Cardiovasc Interv; 2011 Oct; 4(5):463-73. PubMed ID: 21972401
[TBL] [Abstract][Full Text] [Related]
6. Reduction in cardiac mortality with bivalirudin in patients with and without major bleeding: The HORIZONS-AMI trial (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction).
Stone GW; Clayton T; Deliargyris EN; Prats J; Mehran R; Pocock SJ
J Am Coll Cardiol; 2014 Jan 7-14; 63(1):15-20. PubMed ID: 24140664
[TBL] [Abstract][Full Text] [Related]
7. Practice Patterns and In-Hospital Outcomes Associated With Bivalirudin Use Among Patients With Non-ST-Segment-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention in the United States.
Secemsky EA; Kirtane A; Bangalore S; Jovin IS; Patel D; Ferro EG; Wimmer NJ; Roe M; Dai D; Mauri L; Yeh RW
Circ Cardiovasc Qual Outcomes; 2017 Sep; 10(9):. PubMed ID: 28855222
[TBL] [Abstract][Full Text] [Related]
8. Anticoagulant Use Among Patients With End-Stage Renal Disease Undergoing Percutaneous Coronary Intervention: An Analysis From the National Cardiovascular Data Registry.
Washam JB; Kaltenbach LA; Wojdyla DM; Patel MR; Klein AJ; Abbott JD; Rao SV
Circ Cardiovasc Interv; 2018 Feb; 11(2):e005628. PubMed ID: 29432119
[TBL] [Abstract][Full Text] [Related]
9. Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in high-risk patients undergoing percutaneous coronary intervention (from the Anti-Thrombotic Strategy for Reduction of Myocardial Damage During Angioplasty-Bivalirudin vs Heparin study).
Patti G; Pasceri V; D'Antonio L; D'Ambrosio A; Macrì M; Dicuonzo G; Colonna G; Montinaro A; Di Sciascio G
Am J Cardiol; 2012 Aug; 110(4):478-84. PubMed ID: 22583760
[TBL] [Abstract][Full Text] [Related]
10. Meta-analysis comparing bivalirudin versus heparin monotherapy on ischemic and bleeding outcomes after percutaneous coronary intervention.
Bertrand OF; Jolly SS; Rao SV; Patel T; Belle L; Bernat I; Parodi G; Costerousse O; Mann T
Am J Cardiol; 2012 Aug; 110(4):599-606. PubMed ID: 22591669
[TBL] [Abstract][Full Text] [Related]
11. Impact of bivalirudin on post-procedural epicardial blood flow, risk of stent thrombosis and mortality after percutaneous coronary intervention.
Fiedler KA; Ndrepepa G; Schulz S; Floh S; Hoppmann P; Kufner S; Bernlochner I; Byrne RA; Schunkert H; Laugwitz KL; Kastrati A
EuroIntervention; 2016 Feb; 11(11):e1275-82. PubMed ID: 26865445
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of bivalirudin in patients with diabetes mellitus undergoing percutaneous coronary intervention in current clinical practice.
Kim LK; Wong SC; Minutello RM; Bergman G; Feldman DN
J Invasive Cardiol; 2010 Mar; 22(3):94-100. PubMed ID: 20197573
[TBL] [Abstract][Full Text] [Related]
13. The impact of unfractionated heparin or bivalirudin on patients with stable coronary artery disease undergoing percutaneous coronary intervention.
Lima FV; Gruberg L; Aslam U; Ramgadoo M; Clase K; Trevisan A; Jeremias A
J Interv Cardiol; 2018 Apr; 31(2):177-184. PubMed ID: 29205487
[TBL] [Abstract][Full Text] [Related]
14. Meta-Analysis of Effects of Bivalirudin Versus Heparin on Myocardial Ischemic and Bleeding Outcomes After Percutaneous Coronary Intervention.
Barria Perez AE; Rao SV; Jolly SJ; Pancholy SB; Plourde G; Rimac G; Poirier Y; Costerousse O; Bertrand OF
Am J Cardiol; 2016 Apr; 117(8):1256-66. PubMed ID: 26899489
[TBL] [Abstract][Full Text] [Related]
15. Collagen plug vascular closure devices and reduced risk of bleeding with bivalirudin versus heparin plus abciximab in patients undergoing percutaneous coronary intervention for non st-segment elevation myocardial infarction.
Leibundgut G; Pache J; Schulz S; Berger PB; Ferenc M; Gick M; Mehilli J; Kastrati A; Neumann FJ
J Interv Cardiol; 2013 Dec; 26(6):623-9. PubMed ID: 24118114
[TBL] [Abstract][Full Text] [Related]
16. Bivalirudin in patients undergoing primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: outcomes in a large real-world population.
Shelton R; Eftychiou C; Somers K; Liu A; Burton-Wood N; Anderson M; Makri L; Blaxill J; McLenachan J; Wheatcroft S; Greenwood J; Blackman D
EuroIntervention; 2013 May; 9(1):118-24. PubMed ID: 23410540
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and Safety of Bivalirudin During Percutaneous Coronary Intervention in Acute Coronary Syndrome in the Real World: CARTAGOMAX Study.
Cascón-Pérez JD; Abellán-Huerta J; Giner-Caro JA; Dau-Villareal DF; Mármol-Lozano R; Jaulent-Huertas L; Bonilla-Pacheco YI; Ruiz-Abellón Mdel C; Picó-Aracil F; Castillo-Moreno JA
J Cardiovasc Pharmacol; 2016 Sep; 68(3):248-56. PubMed ID: 27261930
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of a prolonged bivalirudin infusion after urgent and complex percutaneous coronary interventions: a descriptive study.
Cortese B; Micheli A; Picchi A; Bandinelli L; Brizi MG; Severi S; Limbruno U
Coron Artery Dis; 2009 Aug; 20(5):348-53. PubMed ID: 19543084
[TBL] [Abstract][Full Text] [Related]
19. Bivalirudin or Heparin in Patients Undergoing Invasive Management of Acute Coronary Syndromes.
Gargiulo G; Carrara G; Frigoli E; Vranckx P; Leonardi S; Ciociano N; Campo G; Varbella F; Calabrò P; Garducci S; Iannone A; Briguori C; Andò G; Crimi G; Limbruno U; Garbo R; Sganzerla P; Russo F; Lupi A; Cortese B; Ausiello A; Ierna S; Esposito G; Zavalloni D; Santarelli A; Sardella G; Tresoldi S; de Cesare N; Sciahbasi A; Zingarelli A; Tosi P; van 't Hof A; Omerovic E; Brugaletta S; Windecker S; Valgimigli M
J Am Coll Cardiol; 2018 Mar; 71(11):1231-1242. PubMed ID: 29544607
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of prehospital administration of unfractionated heparin, enoxaparin or bivalirudin in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Insights from the ORBI registry.
Auffret V; Leurent G; Boulmier D; Bedossa M; Zabalawi A; Hacot JP; Coudert I; Filippi E; Castellant P; Rialan A; Rouault G; Druelles P; Boulanger B; Treuil J; Avez B; Le Guellec M; Gilard M; Le Breton H
Arch Cardiovasc Dis; 2016 Dec; 109(12):696-707. PubMed ID: 27818120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
